Home › NDC Lookup › RxCUI directory › RxCUI 2606782

Zonisamide 20 MG/ML Oral Suspension — RxCUI 2606782

RxNorm drug concept · Semantic clinical drug
RxCUI 2606782 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2606782
Official nameZonisamide 20 MG/ML Oral Suspension
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known aszonisamide 100 MG per 5 ML Oral Suspension; zonisamide 100 MG in 5 mL Oral Suspension
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)37,885 prescriptions · 50 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Zonisamide: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It's added to your other medicines to help control partial seizures. The capsules (Zonegran and generic zonisamide) are for adults with epilepsy. Zonisade liquid is for adults and...
  • Take it by mouth once or twice a day, with or without food. Swallow capsules whole. If you use Zonisade liquid, shake it well and measure with the device your pharmacist gives you,...
  • Sleepiness, dizziness, poor balance, loss of appetite, irritability, headache, nausea and trouble with memory or focus are the most common. Many are dose-related, so tell your pres...
  • Call for any new rash, fever with swollen glands, eye pain or sudden vision changes, or mood changes and thoughts of self-harm. Also call for fast breathing, unusual tiredness, or...
📖 Read our full Zonisamide guide →

🕸️ Concept Web — How Zonisamide 20 MG/ML Oral Suspension Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Zonisamide 20 MG/ML Oral Suspension RxCUI 2606782

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Zonisamide 39998
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Zonisade 2606783
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Zonisamide Oral Suspension 2606781
    • Zonisamide Oral Liquid Product 2606780
    • Zonisamide Oral Product 1156263
    • Zonisamide Oral Suspension [Zonisade] 2606787
    • Zonisade Oral Liquid Product 2606786
    • Zonisade Oral Product 2606785
    • Oral Suspension 316969
    • Oral Liquid Product 1151137
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Zonisamide 20 MG/ML SCDC · 2606779
  • Zonisamide Oral Suspension SCDF · 2606781
  • Zonisamide Oral Liquid Product SCDG · 2606780
  • Zonisamide Oral Product SCDG · 1156263

Brand-Name Concepts

  • Zonisamide 20 MG/ML Oral Suspension [Zonisade] SBD · 2606788
  • Zonisamide 20 MG/ML [Zonisade] SBDC · 2606784
  • Zonisamide Oral Suspension [Zonisade] SBDF · 2606787
  • Zonisade Oral Liquid Product SBDG · 2606786
  • Zonisade Oral Product SBDG · 2606785
  • Zonisade BN · 2606783

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 2606782 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
52652-8001-01 1 BOTTLE in 1 CARTON (52652-8001-1) / 150 mL in 1 BOTTLE ZONISADE Azurity Pharmaceuticals, Inc. 2022-07-15
Observed labelers: Azurity Pharmaceuticals, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ml · median
$2.7509
Range $2.7509–$2.7509 · middle 50% $2.7509–$2.7509 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.